Antibe Therapeutics Inc(Pre-Merger) ATBPF

Interesting

[Ryeman40]

https://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&NR=2022115952A1&KC=A1&FT=D&ND=3&date=20220609&DB=EPODOC&locale=en_EP&fbclid=IwAR1rD12AEleEx7sdA-ZHePmKztAJTdW4PXUN9XXpLOJeIBGvoEx-IlawPTs

[MrMugsy]

Yes - he's co-chair of our scientific advisory board and he likely works closely with Dan at the University of Calgary - where a lot of our 429/IBD work seems to have  been done. Respiratory Diseases is one of the items in our product funnel and we know they are looking in this direction. Sounds good !

[MrMugsy]

Upon further investigation, this is ATB-344 and it's using the NSAID Indomethacin.

[MrMugsy]

Was compared to Regeneron and to ATB-429 ... looks like 344 came out on top.

[themagicbox]

Indomethacin, huh. Usually thats prescribed for a gout flare up. 

[MrMugsy]

Correct !  Never know where the best delivery is going to come from.  Here's a 2006 study for Indomethacin re. SARS ... -------------------------- Indomethacin has a potent antiviral activity against SARS coronavirus (2006) https://pubmed.ncbi.nlm.nih.gov/17302372/

[MrMugsy]

Interesting ... if we look back at the 2013 preliminary prespectus, we see ... 1.  346 - Naproxen identified for OA, RA, Ankylosing Spondylitis, dysmenorrhea, dental pain and general pain. 2.  344 - Indomethacin, for acute gout 3.  Other candidates --------------------------------- Market size for 344 was identified at $500M 

[Chianchin]

Ten Years later .....still dreams and pies in the sky and no food on the table 

[StockingUp21]

9 years later how is the progress